Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | CHIEF FINANCIAL OFFICER | April 14, 2026 | May 18, 2026 |
| Jasper Therapeutics, Inc.AMHCU · Entity 7588 | Director | November 19, 2019 | November 20, 2019 |
| Sigilon Therapeutics, Inc.SGTX · Entity 11481 | CHIEF FINANCIAL OFFICER | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date April 14, 2026 · Filed May 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $29.29 · Expires 2036-04-14 | Direct | 164,309 |
Reported balance
After 2026-04-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-14 · Grant · Acquired 164,309 · Balance 164,309 F1: The stock option vests with respect to 25% of the underlying shares on April 14, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests with respect to 25% of the underlying shares on April 14, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Jasper Therapeutics, Inc.
Report date November 19, 2019 · Filed November 20, 2019
This filing explicitly reported no securities owned.
Sigilon Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.81 · Expires 2031-02-10 | Direct | 55,000 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 55,000 · Balance 55,000 F1: The option vest as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vest as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 14, 2026 Filed May 18, 2026 16:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 164,309 | $0.00 Strike: $29.29 | $0.00 |
DisclosureSEC source: 0001790218-26-000005 · form4-05182026_080501.xml · derivative · entry 1 Reicin Glenn · CIK 0001790218 · CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,309 Underlying: Common Stock · 164,309 shares Expires 2036-04-14 F1 · derivative.exercise_date: The stock option vests with respect to 25% of the underlying shares on April 14, 2027, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 08:00 UTC | Sigilon Therapeutics, Inc. SGTX · Entity 11481 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $39.81 | $0.00 |
DisclosureSEC source: 0001415889-21-000693 · form4-02162021_080216.xml · derivative · entry 1 Reicin Glenn · CIK 0001790218 · CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2031-02-10 F1 · derivative.exercise_date: The option vest as to 25% of the underlying shares of common stock on February 11, 2022, the first anniversary of the vesting commencement date, and at a rate of 6.25% of the underlying shares thereafter on the first day of each quarter following such date until the option is fully vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.